Circulation: Genomic and Precision Medicine最新文献

筛选
英文 中文
Sex-Specific Association Between Genetic Risk of Psychiatric Disorders and Cardiovascular Diseases. 精神疾病和心血管疾病遗传风险的性别特异性关联
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-12-01 Epub Date: 2024-11-29 DOI: 10.1161/CIRCGEN.124.004685
Jiayue-Clara Jiang, Kritika Singh, Rachana Nitin, Lea K Davis, Naomi R Wray, Sonia Shah
{"title":"Sex-Specific Association Between Genetic Risk of Psychiatric Disorders and Cardiovascular Diseases.","authors":"Jiayue-Clara Jiang, Kritika Singh, Rachana Nitin, Lea K Davis, Naomi R Wray, Sonia Shah","doi":"10.1161/CIRCGEN.124.004685","DOIUrl":"10.1161/CIRCGEN.124.004685","url":null,"abstract":"<p><strong>Background: </strong>Though epidemiological studies show increased cardiovascular disease (CVD) risks among individuals with psychiatric disorders, findings on sex differences in comorbidity have been inconsistent.</p><p><strong>Methods: </strong>This genetic epidemiology study examined the sex-specific association between the genetic risk of 3 psychiatric disorders (major depression [MD], schizophrenia, and bipolar disorder), estimated using polygenic scores (PGSs), and risks of 3 CVDs (atrial fibrillation [AF], coronary artery disease [CAD], and heart failure [HF]) in 345 169 European-ancestry individuals (UK Biobank), with analyses replicated in an independent BioVU cohort (n=49 057). Mediation analysis was conducted to determine whether traditional CVD risk factors could explain any observed sex difference.</p><p><strong>Results: </strong>In the UK Biobank, a 1-SD increase in PGS<sub>MD</sub> was significantly associated with the incident risks of all 3 CVDs in females after multiple testing corrections (hazard ratio [HR]<sub>AF-female</sub>=1.04 [95% CI, 1.02-1.06]; <i>P</i>=1.5×10<sup>-</sup><sup>4</sup>; HR<sub>CAD-female</sub>=1.07 [95% CI, 1.04-1.11]; <i>P</i>=2.6×10<sup>-</sup><sup>6</sup>; and HR<sub>HF-female</sub>=1.09 [95% CI, 1.06-1.13]; <i>P</i>=9.7×10<sup>-</sup><sup>10</sup>), but not in males. These female-specific associations remained even in the absence of any psychiatric disorder diagnosis or psychiatric medication use. Although mediation analysis demonstrated that the association between PGS<sub>MD</sub> and CVDs in females was partly mediated by baseline body mass index, hypercholesterolemia, hypertension, and smoking, these risk factors did not explain the higher risk compared with males. The association between PGS<sub>MD</sub> and CAD was consistent between females who were premenopausal and postmenopausal at baseline, while the association with AF and HF was only observed in the baseline postmenopausal cohort. No significant association with CVD risks was observed for the PGS of schizophrenia or bipolar disorder. The female-specific positive association of PGS<sub>MD</sub> with CAD risk was replicated in BioVU.</p><p><strong>Conclusions: </strong>Genetic predisposition to MD confers a greater risk of CVDs in females versus males, even in the absence of any depression diagnosis. This study warrants further investigation into whether genetic predisposition to depression could be useful for improving cardiovascular risk prediction, especially in women.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004685"},"PeriodicalIF":6.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient Perceptions of Emerging Gene Therapies for Arrhythmogenic Right Ventricular Cardiomyopathy. 心律失常性右室心肌病患者对新兴基因疗法的认知。
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-12-01 Epub Date: 2024-11-29 DOI: 10.1161/CIRCGEN.124.004759
Emma M Schopp, Leonore Okwara, Crystal Tichnell, Amy Turriff, Brittney Murray, Andreas S Barth, Hugh Calkins, Leila Jamal, Cynthia A James
{"title":"Patient Perceptions of Emerging Gene Therapies for Arrhythmogenic Right Ventricular Cardiomyopathy.","authors":"Emma M Schopp, Leonore Okwara, Crystal Tichnell, Amy Turriff, Brittney Murray, Andreas S Barth, Hugh Calkins, Leila Jamal, Cynthia A James","doi":"10.1161/CIRCGEN.124.004759","DOIUrl":"10.1161/CIRCGEN.124.004759","url":null,"abstract":"<p><strong>Background: </strong>No disease-specific therapy currently exists for arrhythmogenic right ventricular cardiomyopathy (ARVC), a progressive cardiogenetic condition conferring elevated risk for ventricular arrhythmias, heart failure, and sudden cardiac death. Emerging gene therapies have the potential to fill this gap. However, little is known about how adults with ARVC, or any other inherited cardiomyopathy or arrhythmia syndrome, appraise the risks and benefits of gene therapy research and which considerations may influence their decisions about clinical trial participation.</p><p><strong>Methods: </strong>Twenty adults with clinically diagnosed and gene-positive ARVC participated in semi-structured interviews that explored perceptions of gene therapy and hypothetical decision-making for gene therapy clinical trial participation. Interview transcripts were qualitatively coded and analyzed.</p><p><strong>Results: </strong>Participants expressed enthusiasm for gene therapy with varied levels of personal interest in trial participation. Although clinical severity appeared to be associated with an elevated interest in early trial participation, participants anticipated weighing both personal and trial-specific factors including life stage, trial stage, risks, benefits, participation burden, study leadership, and anticipated cost of future gene therapy. Adaptation to living with ARVC and involvement in the ARVC patient community were also relevant to decision-making about trial participation. Potential ethical concerns included unquestioning trust in clinical teams collaborating on industry-led trials and vulnerability of those recently diagnosed or with high perceived severity of ARVC symptoms.</p><p><strong>Conclusions: </strong>Several characteristics of the individual and trial warrant consideration during the informed consent process. Insights from this study may affect trial planning and communication with participants who have inherited cardiac conditions.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004759"},"PeriodicalIF":6.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polygenic Prediction of Recurrent Events After Early-Onset Myocardial Infarction. 早发性心肌梗死后复发事件的多基因预测。
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-12-01 Epub Date: 2024-11-29 DOI: 10.1161/CIRCGEN.124.004687
Maddalena Ardissino, Elvezia Maria Paraboschi, Samuel A Lambert, Lois G Kim, Martin Kelemen, Giuseppe Maglietta, Antonio Crocamo, Giulia Magnani, Serena Bricoli, Luigi Vignali, Giampaolo Niccoli, Marco Tubaro, Libor Pastika, Arunashis Sau, Fu Siong Ng, Antonio de Marvao, Michael C Honigberg, Pradeep Natarajan, Adam J Nelson, Michael Inouye, Emanuele Di Angelantonio, Rosanna Asselta, Diego Ardissino, Adam S Butterworth
{"title":"Polygenic Prediction of Recurrent Events After Early-Onset Myocardial Infarction.","authors":"Maddalena Ardissino, Elvezia Maria Paraboschi, Samuel A Lambert, Lois G Kim, Martin Kelemen, Giuseppe Maglietta, Antonio Crocamo, Giulia Magnani, Serena Bricoli, Luigi Vignali, Giampaolo Niccoli, Marco Tubaro, Libor Pastika, Arunashis Sau, Fu Siong Ng, Antonio de Marvao, Michael C Honigberg, Pradeep Natarajan, Adam J Nelson, Michael Inouye, Emanuele Di Angelantonio, Rosanna Asselta, Diego Ardissino, Adam S Butterworth","doi":"10.1161/CIRCGEN.124.004687","DOIUrl":"10.1161/CIRCGEN.124.004687","url":null,"abstract":"<p><strong>Background: </strong>Myocardial infarction (MI) is a complex disease caused by both lifestyle and genetic factors. This study aims to investigate the predictive value of genetic risk, in addition to traditional cardiovascular risk factors, for recurrent events following early-onset MI.</p><p><strong>Methods: </strong>The Italian Genetic Study of Early-Onset Myocardial Infarction is a cohort study enrolling patients with MI before 45 years. Monogenic variants causing familial hypercholesterolemia were identified, and a coronary artery disease polygenic score (PGS) was calculated. Ten-fold cross-validated Cox proportional hazards models were fitted sequentially including all clinical variables, the PGS, and monogenic variants on the composite outcome of cardiovascular death, recurrent MI, stroke, or revascularization.</p><p><strong>Results: </strong>During a 19.9-year follow-up, 847 (50.7%) patients experienced recurrent events. Each 1-SD higher PGS was associated with a 21% higher hazard of recurrent events (hazard ratio, 1.21 [95% CI, 1.13-1.31]; <i>P</i>=4.04×10<sup>-6</sup>). Except for secondary prevention, PGS was the strongest determinant of recurrent event risk (C index, 0.56 [95% CI, 0.54-0.58]) compared with clinical risk factors. Overall, predictive performance of clinical risk factors (C index, 0.69 [95% CI, 0.67-0.71]) improved after adding the PGS (C index, 0.69 [95% CI, 0.68-0.71]; <i>P</i>=0.006). When dividing the population by PGS quintiles, the highest fifth had a 57% higher hazard of recurrent events than the lowest fifth (hazard ratio, 1.57 [95% CI, 1.26-1.96]; <i>P</i>=5.57×10<sup>-5</sup>).</p><p><strong>Conclusions: </strong>When compared with other clinical risk factors, PGS was the strongest predictor of event recurrence among patients with an early-onset MI. Though the discriminative power of recurrent event prediction in this cohort was modest, the addition of PGS significantly improved discrimination.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004687"},"PeriodicalIF":6.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polygenic Risk in Families With Dilated Cardiomyopathy. 扩张型心肌病家族的多基因风险
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-10-01 Epub Date: 2024-09-26 DOI: 10.1161/CIRCGEN.124.004558
Jamie-Lee M Thompson, Renee Johnson, Michael Troup, Emma M Rath, Paul E Young, Magdalena J Soka, Monique Ohanian, Ingrid S Tarr, Eleni Giannoulatou, Diane Fatkin
{"title":"Polygenic Risk in Families With Dilated Cardiomyopathy.","authors":"Jamie-Lee M Thompson, Renee Johnson, Michael Troup, Emma M Rath, Paul E Young, Magdalena J Soka, Monique Ohanian, Ingrid S Tarr, Eleni Giannoulatou, Diane Fatkin","doi":"10.1161/CIRCGEN.124.004558","DOIUrl":"10.1161/CIRCGEN.124.004558","url":null,"abstract":"","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004558"},"PeriodicalIF":6.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polygenic Scoring for Detection of Ascending Thoracic Aortic Dilation. 检测升主动脉扩张的多基因评分法
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-10-01 Epub Date: 2024-09-26 DOI: 10.1161/CIRCGEN.123.004512
John DePaolo, Gina Biagetti, Renae Judy, Grace J Wang, John J Kelly, Amit Iyengar, Nicholas J Goel, Nimesh D Desai, Wilson Y Szeto, Joseph E Bavaria, Michael G Levin, Scott M Damrauer
{"title":"Polygenic Scoring for Detection of Ascending Thoracic Aortic Dilation.","authors":"John DePaolo, Gina Biagetti, Renae Judy, Grace J Wang, John J Kelly, Amit Iyengar, Nicholas J Goel, Nimesh D Desai, Wilson Y Szeto, Joseph E Bavaria, Michael G Levin, Scott M Damrauer","doi":"10.1161/CIRCGEN.123.004512","DOIUrl":"10.1161/CIRCGEN.123.004512","url":null,"abstract":"<p><strong>Background: </strong>Ascending thoracic aortic dilation is a complex heritable trait that involves modifiable and nonmodifiable risk factors. Polygenic scores (PGS) are increasingly used to assess risk for complex diseases. The degree to which a PGS can improve aortic diameter prediction in diverse populations is unknown. Presently, we tested whether adding a PGS to clinical prediction algorithms improves performance in a diverse biobank.</p><p><strong>Methods: </strong>The analytic cohort comprised 6235 Penn Medicine Biobank participants with available echocardiography and clinical data linked to genome-wide genotype data. Linear regression models were used to integrate PGS weights derived from a genome-wide association study of thoracic aortic diameter performed in the UK Biobank and were compared with the performance of the previously published aorta optimized regression for thoracic aneurysm (AORTA) score.</p><p><strong>Results: </strong>Cohort participants had a median age of 61 years (IQR, 53-70) and a mean ascending aortic diameter of 3.36 cm (SD, 0.49). Fifty-five percent were male, and 33% were genetically similar to an African reference population. Compared with the AORTA score, which explained 30.6% (95% CI, 29.9%-31.4%) of the variance in aortic diameter, AORTA score+UK Biobank-derived PGS explained 33.1%, (95% CI, 32.3%-33.8%), the reweighted AORTA score explained 32.5% (95% CI, 31.8%-33.2%), and the reweighted AORTA score+UK Biobank-derived PGS explained 34.9% (95% CI, 34.2%-35.6%). When stratified by population, models including the UK Biobank-derived PGS consistently improved upon the clinical AORTA score among individuals genetically similar to a European reference population but conferred minimal improvement among individuals genetically similar to an African reference population. Comparable performance disparities were observed in models developed to discriminate cases/noncases of thoracic aortic dilation (≥4.0 cm).</p><p><strong>Conclusions: </strong>We demonstrated that inclusion of a UK Biobank-derived PGS to the AORTA score confers a clinically meaningful improvement in model performance only among individuals genetically similar to European reference populations and may exacerbate existing health care disparities.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004512"},"PeriodicalIF":6.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Common SYNE2 Genetic Variant Associated With Atrial Fibrillation Lowers Expression of Nesprin-2α1 With Downstream Effects on Nuclear and Electrophysiological Traits. 与心房颤动有关的常见 SYNE2 基因变异会降低 Nesprin-2α1 的表达,并对核和电生理特征产生下游影响。
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-10-01 Epub Date: 2024-10-02 DOI: 10.1161/CIRCGEN.124.004750
Nana Liu, Jeffrey Hsu, Gautam Mahajan, Han Sun, Kenneth R Laurita, Sathyamangla V Naga Prasad, John Barnard, David R Van Wagoner, Chandrasekhar R Kothapalli, Mina K Chung, Jonathan D Smith
{"title":"Common <i>SYNE2</i> Genetic Variant Associated With Atrial Fibrillation Lowers Expression of Nesprin-2α1 With Downstream Effects on Nuclear and Electrophysiological Traits.","authors":"Nana Liu, Jeffrey Hsu, Gautam Mahajan, Han Sun, Kenneth R Laurita, Sathyamangla V Naga Prasad, John Barnard, David R Van Wagoner, Chandrasekhar R Kothapalli, Mina K Chung, Jonathan D Smith","doi":"10.1161/CIRCGEN.124.004750","DOIUrl":"10.1161/CIRCGEN.124.004750","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation GWAS (genome-wide association studies) identified significant associations for rs1152591 and linked variants in the <i>SYNE2</i> gene encoding Nesprin-2, which connects the nuclear membrane with the cytoskeleton.</p><p><strong>Methods: </strong>Reporter gene vector transfection and CRISPR-Cas9 editing were used to identify the causal variant regulating the expression of <i>SYNE2α1</i>. After <i>SYNE2</i> knockdown or <i>SYNE2α1</i> overexpression in human stem cell-derived cardiomyocytes, nuclear phenotypes were assessed by imaging and atomic force microscopy. Gene expression was assessed by RNAseq and gene set enrichment analysis. Fura-2 AM staining assessed calcium transients. Optical mapping assessed action potential duration and conduction velocity.</p><p><strong>Results: </strong>The risk allele of rs1152591 had lower promoter and enhancer activity and was significantly associated with lower expression of the short <i>SYNE2α1</i> isoform in human stem cell-derived cardiomyocytes, without an effect on the expression of the full-length <i>SYNE2</i> mRNA. <i>SYNE2α1</i> overexpression had dominant negative effects on the nucleus with its overexpression or <i>SYNE2</i> knockdown leading to increased nuclear area and decreased nuclear stiffness. Gene expression results from <i>SYNE2α1</i> overexpression demonstrated both concordant and nonconcordant effects with <i>SYNE2</i> knockdown. <i>SYNE2α1</i> overexpression had a gain of function on electrophysiology, leading to significantly faster calcium reuptake and decreased assessed action potential duration, while <i>SYNE2</i> knockdown showed both shortened assessed action potential duration and decreased conduction velocity.</p><p><strong>Conclusions: </strong>rs1152591 was identified as a causal atrial fibrillation variant, with the risk allele decreasing <i>SYNE2α1</i> expression. Downstream effects of <i>SYNE2α1</i> overexpression include changes in nuclear stiffness and electrophysiology, which may contribute to the mechanism for the risk allele's association with AF.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004750"},"PeriodicalIF":6.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Calmodulin in Cardiac Disease: Insights on Genotype and Phenotype. 钙调蛋白在心脏病中的作用:基因型和表型的启示
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-10-01 Epub Date: 2024-09-09 DOI: 10.1161/CIRCGEN.124.004542
Peter J Schwartz, Lia Crotti, Mette Nyegaard, Michael Toft Overgaard
{"title":"Role of Calmodulin in Cardiac Disease: Insights on Genotype and Phenotype.","authors":"Peter J Schwartz, Lia Crotti, Mette Nyegaard, Michael Toft Overgaard","doi":"10.1161/CIRCGEN.124.004542","DOIUrl":"10.1161/CIRCGEN.124.004542","url":null,"abstract":"<p><p>Calmodulin, a protein critically important for the regulation of all major cardiac ion channels, is the quintessential cellular calcium sensor and plays a key role in preserving cardiac electrical stability. Its unique importance is highlighted by the presence of 3 genes in 3 different chromosomes encoding for the same protein and by their extreme conservation. Indeed, all 3 calmodulin (<i>CALM</i>) genes are among the most constrained genes in the human genome, that is, the observed variants are much less than expected by chance. Not surprisingly, <i>CALM</i> variants are poorly tolerated and accompany significant clinical phenotypes, of which the most important are those associated with increased risk for life-threatening arrhythmias. Here, we review the current knowledge about calmodulin, its specific physiological, structural, and functional characteristics, and its importance for cardiovascular disease. Given our role in the development of this knowledge, we also share some of our views about currently unanswered questions, including the rational approaches to the clinical management of the affected patients. Specifically, we present some of the most critical information emerging from the International Calmodulinopathy Registry, which we established 10 years ago. Further progress clearly requires deep phenotypic information on as many carriers as possible through international contributions to the registry, in order to expand our knowledge about Calmodulinopathies and guide clinical management.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004542"},"PeriodicalIF":6.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteome- and Transcriptome-Wide Genetic Analysis Identifies Biological Pathways and Candidate Drug Targets for Preeclampsia. 蛋白质组和转录组全遗传分析确定了子痫前期的生物通路和候选药物靶点。
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-10-01 Epub Date: 2024-08-09 DOI: 10.1161/CIRCGEN.124.004755
Maddalena Ardissino, Buu Truong, Eric A W Slob, Art Schuermans, Satoshi Yoshiji, Alec P Morley, Stephen Burgess, Fu Siong Ng, Antonio de Marvao, Pradeep Natarajan, Kypros Nicolaides, Liam Gaziano, Adam Butterworth, Michael C Honigberg
{"title":"Proteome- and Transcriptome-Wide Genetic Analysis Identifies Biological Pathways and Candidate Drug Targets for Preeclampsia.","authors":"Maddalena Ardissino, Buu Truong, Eric A W Slob, Art Schuermans, Satoshi Yoshiji, Alec P Morley, Stephen Burgess, Fu Siong Ng, Antonio de Marvao, Pradeep Natarajan, Kypros Nicolaides, Liam Gaziano, Adam Butterworth, Michael C Honigberg","doi":"10.1161/CIRCGEN.124.004755","DOIUrl":"10.1161/CIRCGEN.124.004755","url":null,"abstract":"<p><strong>Background: </strong>Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality. However, the current understanding of its underlying biological pathways remains limited.</p><p><strong>Methods: </strong>In this study, we performed a cross-platform proteome- and transcriptome-wide genetic analysis aimed at evaluating the causal relevance of >2000 circulating proteins with preeclampsia, supported by data on the expression of over 15 000 genes across 36 tissues leveraging large-scale preeclampsia genetic association data from women of European ancestry.</p><p><strong>Results: </strong>We demonstrate genetic associations of 18 circulating proteins with preeclampsia (SULT1A1 [sulfotransferase 1A1], SH2B3 [SH2B adapter protein 3], SERPINE2 [serpin family E member 2], RGS18 [regulator of G-protein signaling 18], PZP [pregnancy zone protein], NOTUM [notum, palmitoleoyl-protein carboxylesterase], METAP1 [methionyl aminopeptidase 1], MANEA [mannosidase endo-alpha], jun-D [JunD proto-oncogene], GDF15 [growth differentiation factor 15], FGL1 [fibrinogen like 1], FGF5 [fibroblast growth factor 5], FES [FES proto-oncogene], APOBR [apolipoprotein B receptor], ANP [natriuretic peptide A], ALDH-E2 [aldehyde dehydrogenase 2 family member], ADAMTS13 [ADAM metallopeptidase with thrombospondin type 1 motif 13], and 3MG [N-methylpurine DNA glycosylase]), among which 11 were either directly or indirectly supported by gene expression data, 9 were supported by Bayesian colocalization analyses, and 5 (SERPINE2, PZP, FGF5, FES, and ANP) were supported by all lines of evidence examined. Protein interaction mapping identified potential shared biological pathways through natriuretic peptide signaling, blood pressure regulation, immune tolerance, and thrombin activity regulation.</p><p><strong>Conclusions: </strong>This investigation identified multiple targetable proteins linked to cardiovascular, inflammatory, and coagulation pathways, with SERPINE2, PZP, FGF5, FES, and ANP identified as pivotal proteins with likely causal roles in the development of preeclampsia. The identification of these potential targets may guide the development of targeted therapies for preeclampsia.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004755"},"PeriodicalIF":6.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exercise Intolerance and Low Cardiac Filling Pressures in a Woman With a Novel eNOS Mutation. 一名 eNOS 基因突变女性的运动不耐受和低心脏充盈压。
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-10-01 Epub Date: 2024-09-27 DOI: 10.1161/CIRCGEN.124.004741
Sarah McGarrity, David R Ziehr, Christina A Austin-Tse, Marc N Wein, Raghu R Chivukula, William M Oldham
{"title":"Exercise Intolerance and Low Cardiac Filling Pressures in a Woman With a Novel eNOS Mutation.","authors":"Sarah McGarrity, David R Ziehr, Christina A Austin-Tse, Marc N Wein, Raghu R Chivukula, William M Oldham","doi":"10.1161/CIRCGEN.124.004741","DOIUrl":"10.1161/CIRCGEN.124.004741","url":null,"abstract":"","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004741"},"PeriodicalIF":6.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Normal Is Low-Normal Left Ventricular Ejection Fraction in Familial Dilated Cardiomyopathy? 家族性扩张型心肌病左心室射血分数过低有多正常?
IF 6 2区 医学
Circulation: Genomic and Precision Medicine Pub Date : 2024-10-01 Epub Date: 2024-08-08 DOI: 10.1161/CIRCGEN.124.004603
Stacey A Peters, Leah Wright, Samuel J Fogarty, Lauren McCall, Maraed Rosa, Subodh B Joshi, Elaine Lui, Dominica Zentner, Tom Marwick, Diane Fatkin
{"title":"How Normal Is Low-Normal Left Ventricular Ejection Fraction in Familial Dilated Cardiomyopathy?","authors":"Stacey A Peters, Leah Wright, Samuel J Fogarty, Lauren McCall, Maraed Rosa, Subodh B Joshi, Elaine Lui, Dominica Zentner, Tom Marwick, Diane Fatkin","doi":"10.1161/CIRCGEN.124.004603","DOIUrl":"10.1161/CIRCGEN.124.004603","url":null,"abstract":"","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004603"},"PeriodicalIF":6.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信